Journal
ALIMENTARY PHARMACOLOGY & THERAPEUTICS
Volume 39, Issue 2, Pages 176-187Publisher
WILEY
DOI: 10.1111/apt.12556
Keywords
-
Funding
- Vifor Pharma Nordiska AB, Kista, Sweden
Ask authors/readers for more resources
BackgroundNonvariceal acute upper gastrointestinal bleeding (AUGIB) is often accompanied by post-discharge anaemia. AimTo investigate whether iron treatment can effectively treat anaemia and to compare a 3-month regimen of oral iron treatment with a single administration of intravenous iron prior to discharge. MethodsNinety-seven patients with nonvariceal AUGIB and anaemia were enrolled in a double-blind, placebo-controlled, randomised study. The patients were allocated to one of three groups, receiving a single intravenous administration of 1000mg of iron; oral iron treatment, 200mg daily for 3months; or placebo, respectively. The patients were followed up for 3months. ResultsFrom week 4 onwards, patients receiving treatment had significantly higher haemoglobin levels compared with patients who received placebo only. At the end of treatment, the proportion of patients with anaemia was significantly higher in the placebo group (P<0.01) than in the treatment groups. Intravenous iron appeared to be more effective than oral iron in ensuring sufficient iron stores. ConclusionsIron treatment is effective and essential for treating anaemia after nonvariceal acute upper gastrointestinal bleeding. The route of iron supplementation is less important in terms of the increase in haemoglobin levels. Iron stores are filled most effectively if intravenous iron supplementation is administered (ClinicalTrials.gov identifier: NCT00978575).
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available